Literature DB >> 22072678

Spinocerebellar ataxia type 7 cerebellar disease requires the coordinated action of mutant ataxin-7 in neurons and glia, and displays non-cell-autonomous bergmann glia degeneration.

Stephanie A Furrer1, Mathini S Mohanachandran, Sarah M Waldherr, Christopher Chang, Vincent A Damian, Bryce L Sopher, Gwenn A Garden, Albert R La Spada.   

Abstract

Spinocerebellar ataxia type 7 (SCA7) is a dominantly inherited disorder characterized by cerebellum and brainstem neurodegeneration. SCA7 is caused by a CAG/polyglutamine (polyQ) repeat expansion in the ataxin-7 gene. We previously reported that directed expression of polyQ-ataxin-7 in Bergmann glia (BG) in transgenic mice leads to ataxia and non-cell-autonomous Purkinje cell (PC) degeneration. To further define the cellular basis of SCA7, we derived a conditional inactivation mouse model by inserting a loxP-flanked ataxin-7 cDNA with 92 repeats into the translational start site of the murine prion protein (PrP) gene in a bacterial artificial chromosome (BAC). The PrP-floxed-SCA7-92Q BAC mice developed neurological disease, and exhibited cerebellar degeneration and BG process loss. To inactivate polyQ-ataxin-7 expression in specific cerebellar cell types, we crossed PrP-floxed-SCA7-92Q BAC mice with Gfa2-Cre transgenic mice (to direct Cre to BG) or Pcp2-Cre transgenic mice (which yields Cre in PCs and inferior olive). Excision of ataxin-7 from BG partially rescued the behavioral phenotype, but did not prevent BG process loss or molecular layer thinning, while excision of ataxin-7 from PCs and inferior olive provided significantly greater rescue and prevented both pathological changes, revealing a non-cell-autonomous basis for BG pathology. When we prevented expression of mutant ataxin-7 in BG, PCs, and inferior olive by deriving Gfa2-Cre;Pcp2-Cre;PrP-floxed-SCA7-92Q BAC triple transgenic mice, we noted a dramatic improvement in SCA7 disease phenotypes. These findings indicate that SCA7 disease pathogenesis involves a convergence of alterations in a variety of different cell types to fully recapitulate the cerebellar degeneration.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22072678      PMCID: PMC3256125          DOI: 10.1523/JNEUROSCI.4000-11.2011

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  30 in total

1.  Cre recombinase expression in cerebellar Purkinje cells.

Authors:  J J Barski; K Dethleffsen; M Meyer
Journal:  Genesis       Date:  2000 Nov-Dec       Impact factor: 2.487

2.  Insulin-like growth factor-1 increases activity and surface levels of the GLAST subtype of glutamate transporter.

Authors:  Citlalli Gamboa; Arturo Ortega
Journal:  Neurochem Int       Date:  2002-04       Impact factor: 3.921

3.  Z/EG, a double reporter mouse line that expresses enhanced green fluorescent protein upon Cre-mediated excision.

Authors:  A Novak; C Guo; W Yang; A Nagy; C G Lobe
Journal:  Genesis       Date:  2000 Nov-Dec       Impact factor: 2.487

4.  Polyglutamine-expanded ataxin-7 upregulates Bax expression by activating p53 in cerebellar and inferior olivary neurons.

Authors:  Hung-Li Wang; An-Hsun Chou; An-Chi Lin; Si-Ying Chen; Yi-Hshin Weng; Tu-Hsueh Yeh
Journal:  Exp Neurol       Date:  2010-05-28       Impact factor: 5.330

5.  Neuron-specific expression of mutant superoxide dismutase 1 in transgenic mice does not lead to motor impairment.

Authors:  A Pramatarova; J Laganière; J Roussel; K Brisebois; G A Rouleau
Journal:  J Neurosci       Date:  2001-05-15       Impact factor: 6.167

6.  Polyglutamine-expanded ataxin-7 antagonizes CRX function and induces cone-rod dystrophy in a mouse model of SCA7.

Authors:  A R La Spada; Y H Fu; B L Sopher; R T Libby; X Wang; L Y Li; D D Einum; J Huang; D E Possin; A C Smith; R A Martinez; K L Koszdin; P M Treuting; C B Ware; J B Hurley; L J Ptácek; S Chen
Journal:  Neuron       Date:  2001-09-27       Impact factor: 17.173

7.  Expanded polyglutamines induce neurodegeneration and trans-neuronal alterations in cerebellum and retina of SCA7 transgenic mice.

Authors:  G Yvert; K S Lindenberg; S Picaud; G B Landwehrmeyer; J A Sahel; J L Mandel
Journal:  Hum Mol Genet       Date:  2000-10-12       Impact factor: 6.150

8.  Polyglutamine-expanded ataxin-7 causes cerebellar dysfunction by inducing transcriptional dysregulation.

Authors:  An-Hsun Chou; Chia-Yang Chen; Si-Ying Chen; Wei-June Chen; Ying-Ling Chen; Yi-Shin Weng; Hung-Li Wang
Journal:  Neurochem Int       Date:  2009-11-10       Impact factor: 3.921

9.  Polyglutamine-expanded ataxin-7 promotes non-cell-autonomous purkinje cell degeneration and displays proteolytic cleavage in ataxic transgenic mice.

Authors:  Gwenn A Garden; Randell T Libby; Ying-Hui Fu; Yoshito Kinoshita; Jing Huang; Daniel E Possin; Annette C Smith; Refugio A Martinez; Gabriel C Fine; Sara K Grote; Carol B Ware; David D Einum; Richard S Morrison; Louis J Ptacek; Bryce L Sopher; Albert R La Spada
Journal:  J Neurosci       Date:  2002-06-15       Impact factor: 6.167

10.  A simple composite phenotype scoring system for evaluating mouse models of cerebellar ataxia.

Authors:  Stephan J Guyenet; Stephanie A Furrer; Vincent M Damian; Travis D Baughan; Albert R La Spada; Gwenn A Garden
Journal:  J Vis Exp       Date:  2010-05-21       Impact factor: 1.355

View more
  28 in total

Review 1.  Intercellular (mis)communication in neurodegenerative disease.

Authors:  Gwenn A Garden; Albert R La Spada
Journal:  Neuron       Date:  2012-03-08       Impact factor: 17.173

2.  Nicotinamide Pathway-Dependent Sirt1 Activation Restores Calcium Homeostasis to Achieve Neuroprotection in Spinocerebellar Ataxia Type 7.

Authors:  Colleen A Stoyas; David D Bushart; Pawel M Switonski; Jacqueline M Ward; Akshay Alaghatta; Mi-Bo Tang; Chenchen Niu; Mandheer Wadhwa; Haoran Huang; Alex Savchenko; Karim Gariani; Fang Xie; Joseph R Delaney; Terry Gaasterland; Johan Auwerx; Vikram G Shakkottai; Albert R La Spada
Journal:  Neuron       Date:  2019-12-16       Impact factor: 17.173

Review 3.  Prion-Like Characteristics of Polyglutamine-Containing Proteins.

Authors:  Margaret M P Pearce; Ron R Kopito
Journal:  Cold Spring Harb Perspect Med       Date:  2018-02-01       Impact factor: 6.915

4.  Early activation of microglia and astrocytes in mouse models of spinocerebellar ataxia type 1.

Authors:  M Cvetanovic; M Ingram; H Orr; P Opal
Journal:  Neuroscience       Date:  2015-01-14       Impact factor: 3.590

5.  Nonallele specific silencing of ataxin-7 improves disease phenotypes in a mouse model of SCA7.

Authors:  Pavitra S Ramachandran; Ryan L Boudreau; Kellie A Schaefer; Albert R La Spada; Beverly L Davidson
Journal:  Mol Ther       Date:  2014-06-16       Impact factor: 11.454

Review 6.  Polyglutamine spinocerebellar ataxias - from genes to potential treatments.

Authors:  Henry L Paulson; Vikram G Shakkottai; H Brent Clark; Harry T Orr
Journal:  Nat Rev Neurosci       Date:  2017-08-17       Impact factor: 34.870

7.  Comparison of spinocerebellar ataxia type 3 mouse models identifies early gain-of-function, cell-autonomous transcriptional changes in oligodendrocytes.

Authors:  Biswarathan Ramani; Bharat Panwar; Lauren R Moore; Bo Wang; Rogerio Huang; Yuanfang Guan; Henry L Paulson
Journal:  Hum Mol Genet       Date:  2017-09-01       Impact factor: 6.150

8.  The first knockin mouse model of episodic ataxia type 2.

Authors:  Samuel J Rose; Lisa H Kriener; Ann K Heinzer; Xueliang Fan; Robert S Raike; Arn M J M van den Maagdenberg; Ellen J Hess
Journal:  Exp Neurol       Date:  2014-08-08       Impact factor: 5.330

9.  The histone deacetylase HDAC3 is essential for Purkinje cell function, potentially complicating the use of HDAC inhibitors in SCA1.

Authors:  Anand Venkatraman; Yuan-Shih Hu; Alessandro Didonna; Marija Cvetanovic; Aleksandar Krbanjevic; Patrice Bilesimo; Puneet Opal
Journal:  Hum Mol Genet       Date:  2014-03-04       Impact factor: 6.150

Review 10.  Polyglutamine Repeats in Neurodegenerative Diseases.

Authors:  Andrew P Lieberman; Vikram G Shakkottai; Roger L Albin
Journal:  Annu Rev Pathol       Date:  2018-08-08       Impact factor: 23.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.